In Vivo Demonstration that Human Parathyroid Hormone 1–38 Inhibits the Expression of Osteoprotegerin in Bone with the Kinetics of an Immediate Early Gene
Open Access
- 1 May 2000
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 15 (5) , 863-871
- https://doi.org/10.1359/jbmr.2000.15.5.863
Abstract
Osteoprotegerin (OPG) is a potent inhibitor of osteoclast formation and function. To elucidate how OPG is regulated in bone, we examined (1) the expression and localization of OPG protein in bone tissue, (2) the effect of human parathyroid hormone 1–38 (hPTH 1–38) on OPG messenger RNA (mRNA) levels in rat femur metaphyseal and diaphyseal bone, and (3) the effect of hPTH(1–38) on expression of OPG mRNA in cultured osteoblast‐like cells derived from the metaphysis and diaphysis, and in ROS 17/2.8 osteosarcoma cells. Because PTH has been shown to stimulate osteoblast activity via the cyclic adenosine monophosphate (cAMP)/protein kinase A (PKA) signal transduction pathway we also investigated whether PTH action on OPG in vivo is dependent on activation of cAMP/PKA pathway. Immunohistochemistry was used to evaluate OPG protein expression and Northern blot hybridization was used to analyze OPG mRNA expression both in vivo and in vitro. Immunohistochemistry of OPG protein expression in the rat distal femur metaphysis revealed that it was localized predominantly in preosteoblasts, osteoblasts, lining cells, and the osteoid layer, with occasional immunoreactivity in osteocytes and cells of the bone marrow. Subcutaneous (sc) administration of a single injection of hPTH(1–38) at 80 μg/kg induced a rapid and transient decrease in OPG mRNA expression in both metaphyseal and diaphyseal bone. The decrease in OPG message was evident by 1 h and mRNA levels returned to baseline after 3 h. PTH analog PTH(1–31), which stimulates intracellular cAMP accumulation, inhibited OPG expression, whereas PTH analogs (3–34 and 7–34) that do not stimulate cAMP production had no effect on expression. In contrast to PTH, prostaglandin E2 (PGE2) had no effect on OPG mRNA expression in vivo in the metaphyseal bone cells, under conditions in which PGE2 does promote expression of the c‐fos gene. The in vivo effects of hPTH(1–38) on OPG mRNA were confirmed in isolated primary osteoblast cultures derived from either metaphyseal or diaphyseal bone as well as in ROS 17/2.8 osteosarcoma cells. We propose that the rapid and transient decrease in OPG expression may initiate a cascade of events resulting in the differentiation of osteoclast progenitor. Such a spatially and temporally programmed effect of PTH might contribute to bone turnover. (J Bone Miner Res 2000;15:863–871)Keywords
This publication has 54 references indexed in Scilit:
- A New Member of Tumor Necrosis Factor Ligand Family, ODF/OPGL/TRANCE/RANKL, Regulates Osteoclast Differentiation and FunctionBiochemical and Biophysical Research Communications, 1999
- Osteoprotegerin and osteoprotegerin ligand effects on osteoclast formation from human peripheral blood mononuclear cell precursorsJournal of Cellular Biochemistry, 1999
- RANK Is the Essential Signaling Receptor for Osteoclast Differentiation Factor in OsteoclastogenesisBiochemical and Biophysical Research Communications, 1998
- Transforming Growth Factor-β1 Increases mRNA Levels of Osteoclastogenesis Inhibitory Factor in Osteoblastic/Stromal Cells and Inhibits the Survival of Murine Osteoclast-like CellsBiochemical and Biophysical Research Communications, 1998
- Regulation of Osteoprotegerin mRNA Levels by Prostaglandin E2in Human Bone Marrow Stroma CellsBiochemical and Biophysical Research Communications, 1998
- Osteoclast Differentiation Factor (ODF) Induces Osteoclast-like Cell Formation in Human Peripheral Blood Mononuclear Cell CulturesBiochemical and Biophysical Research Communications, 1998
- Osteoclast Differentiation Factor Mediates an Essential Signal for Bone Resorption Induced by 1α,25-Dihydroxyvitamin D3, Prostaglandin E2, or Parathyroid Hormone in the Microenvironment of BoneBiochemical and Biophysical Research Communications, 1998
- Characterization of Structural Domains of Human Osteoclastogenesis Inhibitory FactorPublished by Elsevier ,1998
- The Cyclic-AMP Antagonist Adenosine-3′,5′-Cyclic Monophosphosphorothioate, Rp-Isomer Inhibits Parathyroid Hormone-Induced Bone Resorption, in VitroBiochemical and Biophysical Research Communications, 1993
- The activation of cAMP-dependent protein kinase is directly linked to the stimulation of bone resorption by parathyroid hormoneBiochemical and Biophysical Research Communications, 1992